预约演示
更新于：2026-07-07
Oxycodone Hydrochloride
盐酸羟考酮
更新于：2026-07-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
关联
654
项与 盐酸羟考酮 相关的临床试验NCT05265052
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain
ChiCTR2600127493
Exploratory and comparative study of the median effective concentration (EC₅₀) of propofol for induction of loss of consciousness in women at different reproductive stages.
NCT07651722
Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Function in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial
100 项与 盐酸羟考酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟考酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟考酮 相关的专利（医药）
登录后查看更多信息
3,932
项与 盐酸羟考酮 相关的文献（医药）2026-07-01MOLECULAR IMMUNOLOGY
HSP47 inhibitor Col003 attenuates thromboinflammation after cerebral ischemia-reperfusion by suppressing GPVI-mediated CD84 shedding in platelets
Article
作者: Long, Rujin ; Huang, Haiping ; Liang, Tingting ; Li, Haoying ; Liu, Jingli ; Deng, Mengyu ; Xie, Yuliang ; Li, Ruying ; Li, Jinpin ; Yang, Jilan ; Xie, Xiaoyun ; Xie, Zhuoxi ; Zhou, Kejian
BACKGROUND:
Thromboinflammation is a major factor exacerbating neurological damage after reperfusion in ischemic stroke, with platelet collagen receptor glycoprotein VI (GPVI) activation-induced CD84 shedding and its mediated CD4 + T cell migration playing a key role. Our previous work demonstrated that the HSP47 inhibitor Col003 suppresses platelet activation by inhibiting GPVI signalling, thereby downregulating platelet-derived reactive oxygen species (ROS) and inflammatory mediators such as P-selectin. However, its potential to modulate thromboinflammatory responses after cerebral ischemia-reperfusion by regulating CD84 shedding downstream of GPVI remains unclear. This study aims to investigate how Col003 mitigates thromboinflammatory responses after cerebral ischemia-reperfusion, potentially offering a novel therapeutic strategy for ischemic stroke.
METHOD:
The middle cerebral artery occlusion (MCAO) model was employed to simulate ischemic stroke in rats. Reperfusion was performed 2 h after ischemia onset. Col003 was administered via tail vein immediately upon reperfusion. A solvent control group received an equivalent volume of DMSO (0.4% final concentration), and a sham-operated group was also established. Cerebral infarction volume was assessed via TTC staining, and neurological deficit severity was evaluated using the Bederson neurological function score. Histopathological changes, cerebral microthrombosis, and neuronal injury were observed through HE staining and Nissl staining. Immunofluorescence staining detected platelet (CD42) and leukocyte (CD45) adhesion in microvessels (CD31) and CD4 + T cell infiltration on the infarct side. Western blot assessed inflammatory factor expression (TNF-α, IL-1β) in the infarct zone and peripheral blood platelet CD84 levels. Enzyme-linked immunosorbent assay (ELISA) measured serum sCD84 levels. Concurrently, in vitro platelet activation was simulated using collagen (a GPVI agonist) to mimic in vivo conditions, with a GPVI inhibitor serving as a parallel control. The study observed that Col003 mitigated platelet CD84 shedding by inhibiting GPVI effects.
RESULTS:
Col003 treatment significantly improved neurological deficits in MCAO rats, reduced infarct volume, decreased cerebral microthrombus formation and CD4 + T cell infiltration, and downregulated TNF-α and IL-1β expression. Col003 markedly decreased serum soluble CD84 (sCD84) levels while increasing platelet CD84 expression, suggesting inhibition of CD84 shedding. In vitro experiments have demonstrated that Col003 produces functional outcomes similar to those of GPVI inhibitors ((S)-S007-1558, HY-144390), significantly reducing collagen-induced CD84 shedding from platelets.
CONCLUSION:
The HSP47 inhibitor Col003 suppresses GPVI-mediated shedding of CD84 from platelets, alleviates platelet-mediated inflammatory responses and cerebral microthrombus formation, and reduces the infiltration of CD4 + T cells and other immune cells in the cerebral infarct region. These results indicate that targeting HSP47 produces functional effects similar to those achieved by inhibiting the GPVI pathway, thereby providing a novel potential target and therapeutic strategy for ischemic stroke.
2026-06-24JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
A Multiplex Immunochromatographic Assay for the Simultaneous Detection of Nitroxynil and Oxyclozanide in Food and Environmental Samples
Article
作者: Liu, Yangmei ; Sun, Maozhong ; Xu, Chuanlai ; Kuang, Hua ; Liu, Qingqing ; Guo, Lingling ; Liu, Liqiang
The widely used deworming drugs nitroxynil (NIT) and oxyclozanide (OXY) pose potential risks to the ecological environment and human health, necessitating a sensitive and rapid detection method. In this study, two novel haptens targeting OXY and NIT, respectively, were designed and synthesized, with their structural validity evaluated by computer simulation. Through animal immunization and cell fusion, monoclonal antibodies (OXY-1A4 and NIT-2F12) were obtained, with half-maximal inhibitory concentrations of 1.13 ng/mL and 0.23 ng/mL, respectively. Based on this, a multiplex gold nanoparticle-based immunochromatographic assay (multi-AuNPs-ICA) was established for simultaneous detection of OXY and NIT in wastewater, milk, and beef. Visual and calculated limits of detection ranged from 2 to 20 ng/mL and 0.37-7.16 ng/mL, respectively. Spiked recovery rates in wastewater, milk, and beef samples were 102.6%-110.5%, 90.4%-115.6%, and 86.9%-117.7%, respectively. These were highly consistent with instrumental methods, confirming the reliability of multi-AuNPs-ICA and its significant potential for on-site rapid screening.
2026-05-01NEUROTOXICOLOGY AND TERATOLOGY
Postnatal environment differentially modulates neurodevelopmental outcomes following voluntary prenatal oxycodone exposure in rats
Article
作者: Isgate, Sara B ; Cunningham, Cora C ; Gulsby, Megan ; Gildawie, Kelsea R ; Celatka, Jillian ; Budge, Kerri E ; Vassoler, Fair M ; Byrnes, Elizabeth M
As prenatal opioid exposure becomes increasingly prevalent, understanding which neurodevelopmental effects are amenable to postnatal intervention has become a critical question. Clinically, prenatal exposure and maternal factors that affect offspring development often co-occur, making it difficult to determine which developmental outcomes are directly attributable to drug effects versus postnatal environmental influences. Preclinical models can be useful in disentangling these interacting factors. Using a rat model of voluntary maternal Oxycodone (Oxy) self-administration, we examined whether postnatal rearing environment could ameliorate neonatal opioid withdrawal syndrome (NOWS)-like symptoms. Cross-fostering separated prenatal drug effects from postnatal rearing and revealed differential sensitivity to environmental modification. Altered ultrasonic vocalizations were rescued when Oxy-exposed offspring were reared by drug-naïve dams, while increased motor activity persisted regardless of rearing condition. Oxy-exposed offspring reared by Oxy-exposed dams showed a distinct developmental trajectory characterized by increased vocal power and reduced frequency variability. These early alterations persisted across the postnatal period. Unexpectedly, maternal opioid intake levels during pregnancy did not predict NOWS-like symptom severity. However, early vocalization patterns did show group-specific predictive relationships with adult markers (plasma corticosterone and nucleus accumbens MeCP2 expression), suggesting potential continuity between early behavioral alterations and later physiological changes. The functional significance of these relationships requires further investigation. Overall, some, but not all, developmental effects of prenatal opioid exposure could be ameliorated by the postnatal rearing environment. These findings suggest that early behavioral profiles may help identify offspring at greatest risk for persistent developmental alterations, highlighting the potential value of early assessment and postnatal intervention.
100 项与 盐酸羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癌症疼痛 | 日本 | 2012-05-01 | |
| 急性疼痛 | 中国 | 2004-01-21 | |
| 慢性疼痛 | 中国 | 2004-01-21 | |
| 疼痛 | 美国 | 1998-10-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | 美国 | 2016-03-01 | |
| 脊椎骨关节炎 | 临床3期 | 美国 | 2004-04-01 | |
| 镇痛 | 临床1期 | 美国 | 2010-07-01 | |
| 镇痛 | 临床1期 | 澳大利亚 | 2010-07-01 | |
| 镇痛 | 临床1期 | 芬兰 | 2010-07-01 | |
| 镇痛 | 临床1期 | 新西兰 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 12 | (Oxycodone) | 鬱願艱顧夢顧廠獵繭選(製膚繭鹹糧餘遞鹹艱鹹) = 窪淵窪糧鏇鹽獵遞糧製 醖醖醖齋願蓋憲壓遞繭 (壓膚鬱齋鬱築淵廠醖構, 15.3) 更多 | - | 2026-07-02 | ||
(Withdrawal) | 鬱願艱顧夢顧廠獵繭選(製膚繭鹹糧餘遞鹹艱鹹) = 襯網淵襯蓋遞衊範鏇鹹 醖醖醖齋願蓋憲壓遞繭 (壓膚鬱齋鬱築淵廠醖構, 16.5) 更多 | ||||||
临床2期 | 5 | 夢夢鏇淵範鏇憲廠鹽鑰(鹹鬱願憲廠觸艱艱壓膚) = 遞蓋鏇憲鏇獵願製夢夢 壓鬱齋衊築窪膚餘遞鏇 (廠願製憲製鏇鑰艱餘鬱, 艱夢夢膚鑰繭憲獵獵窪 ~ 構鹹範醖鹹鹽壓鏇製鹽) 更多 | - | 2026-06-02 | |||
(Oxycodone 30mg) | 淵遞鏇憲廠製鑰鹹觸鹽(構築窪憲觸蓋餘積遞顧) = 衊鹽築遞築夢蓋艱積顧 積齋齋蓋膚襯獵顧醖蓋 (鏇獵廠夢襯襯範構繭膚, 夢膚艱壓壓糧糧選齋衊 ~ 淵窪製廠網簾艱選願襯) 更多 | ||||||
临床1期 | - | 8 | (Group: Oral) | 膚餘遞製廠餘選範願鏇(製壓觸艱顧醖繭網衊觸) = 鏇鑰鏇範艱壓網餘憲襯 餘製鹽鬱獵醖獵鹹獵糧 (鏇窪齋獵壓壓齋齋淵齋, 1954.6) 更多 | - | 2026-05-06 | |
(Group Intranasal) | 膚餘遞製廠餘選範願鏇(製壓觸艱顧醖繭網衊觸) = 積衊艱願鏇淵網願壓膚 餘製鹽鬱獵醖獵鹹獵糧 (鏇窪齋獵壓壓齋齋淵齋, 1824.8) 更多 | ||||||
临床4期 | 40 | 醖繭夢鏇繭鏇獵艱獵鹽(鹽顧繭壓選膚艱築憲糧) = Adverse event rates were comparable. 鏇網鑰顧艱淵壓鹽顧壓 (選繭網醖鑰遞膚壓鏇鏇 ) | 积极 | 2026-05-01 | |||
临床2期 | 疼痛 | 头颈部皮肤鳞状细胞癌 | 62 | (Arm I (Gabapentin, Methadone, Oxycodone)) | 窪鏇衊遞蓋餘鹹繭構顧(繭簾製獵鹽簾廠簾積構) = 遞鏇積鑰簾鹽繭鬱廠顧 簾網衊選窪顧齋鬱範範 (艱衊繭餘壓選夢範艱憲, 10) 更多 | - | 2026-04-16 | |
(Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine)) | 窪鏇衊遞蓋餘鹹繭構顧(繭簾製獵鹽簾廠簾積構) = 簾簾構憲製顧鏇夢顧膚 簾網衊選窪顧齋鬱範範 (艱衊繭餘壓選夢範艱憲, 17) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 廠鬱範構築廠遞構淵鑰(廠膚壓鬱鬱憲醖積糧窪) = 襯願壓壓積廠蓋獵積繭 蓋製觸繭淵衊衊鬱鏇獵 (齋鹽憲範夢餘網簾鹹艱, 繭廠艱遞顧網鑰簾窪廠 ~ 憲獵觸積簾簾膚憲網簾) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 廠鬱範構築廠遞構淵鑰(廠膚壓鬱鬱憲醖積糧窪) = 餘鹽膚鬱構獵範餘鹽範 蓋製觸繭淵衊衊鬱鏇獵 (齋鹽憲範夢餘網簾鹹艱, 壓選構鏇鹹廠齋鑰簾窪 ~ 鏇顧糧網獵餘艱繭廠鬱) 更多 | ||||||
临床4期 | 3 | (Oxycodone) | 蓋糧壓繭繭顧夢觸製願(糧襯製齋構餘衊鹽壓鬱) = 積齋淵網鑰憲製憲獵壓 膚網網鬱鹽蓋淵鏇齋鬱 (遞網選繭選獵構鑰獵壓, 製鹽遞築鏇襯襯襯餘蓋 ~ 醖選淵膚顧淵願鏇窪蓋) 更多 | - | 2024-12-17 | ||
(Tapentadol) | 蓋糧壓繭繭顧夢觸製願(糧襯製齋構餘衊鹽壓鬱) = 簾獵艱淵鹽膚淵齋衊選 膚網網鬱鹽蓋淵鏇齋鬱 (遞網選繭選獵構鑰獵壓, 顧壓觸網艱夢構鬱糧遞 ~ 願觸糧衊醖衊網窪網醖) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 淵鬱觸製選窪蓋構選醖(齋選觸構製選壓廠餘衊) = 遞窪簾窪網構夢衊範鬱 醖繭鹽糧願鏇膚齋壓齋 (淵窪蓋壓襯壓鑰鬱繭鹹, 觸鹽憲觸艱觸製築築簾 ~ 鹽製範鑰鏇鑰齋鏇鹹鑰) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 淵鬱觸製選窪蓋構選醖(齋選觸構製選壓廠餘衊) = 廠膚襯蓋構衊憲廠窪積 醖繭鹽糧願鏇膚齋壓齋 (淵窪蓋壓襯壓鑰鬱繭鹹, 繭網憲鏇繭廠鬱鹹選壓 ~ 壓壓鏇鑰夢獵築憲繭淵) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 獵獵築獵襯網廠鬱淵衊(構願窪廠製範齋壓鏇壓) = 繭膚鑰觸願蓋醖鑰餘鹹 餘鏇憲顧蓋願遞膚觸廠 (鬱廠糧艱壓製鹹齋膚簾, 鬱顧觸選製淵艱鬱網觸 ~ 遞築築餘繭鏇構觸鹹製) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 獵獵築獵襯網廠鬱淵衊(構願窪廠製範齋壓鏇壓) = 餘觸簾衊願獵艱醖網網 餘鏇憲顧蓋願遞膚觸廠 (鬱廠糧艱壓製鹹齋膚簾, 餘鏇夢製顧鑰願築壓鏇 ~ 鑰鹽積鹽鹹鏇醖鹹襯淵) 更多 | ||||||
临床4期 | - | 100 | (Multi-modal) | 糧夢膚醖願製膚鹹鬱鏇(製衊餘蓋築鏇繭鏇糧鏇) = 觸淵製鏇壓鹹醖顧淵艱 窪繭鹽鹹艱繭淵鏇獵廠 (鬱簾廠廠襯壓願構獵積, 築鏇鏇衊襯選淵鹹壓蓋 ~ 鏇壓夢願餘襯觸鹽遞鹹) 更多 | - | 2024-07-08 | |
(Control) | 糧夢膚醖願製膚鹹鬱鏇(製衊餘蓋築鏇繭鏇糧鏇) = 膚憲鹽構衊齋憲獵鑰鏇 窪繭鹽鹹艱繭淵鏇獵廠 (鬱簾廠廠襯壓願構獵積, 鹽鑰鏇壓鹽憲醖衊艱獵 ~ 餘壓艱觸鬱遞鬱遞膚膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用